Global Laser Probe Market Set For Big Growth - Foresight By 2023

Global Laser Probe Market Information By Product Type (Continuous-Wave (CW) Laser Probe, Pulse Laser Probe), By Probe Type (Single Laser Probe, Cluster laser probe), By Application (Ophthalmology, Dermatology, Rheumatology, Orthopedics, Dentistry), By End-User (Tertiary Hospitals, Clinics) and Region – Forecasts till 2023

Market Scenario:

Laser is view as a highly advanced technology used in imaging diagnostics procedures. Advances in technology and increasing demand for diagnostic services are some of the factors supporting the growth of market. There is a growing need for effective diagnostic technologies, which is creating opportunities for the laser probe market.

The rising prevalence of diseases associated with diabetic retinopathy, cancer and age-related macular diseases has made diagnostics a key healthcare segment. Many of these conditions can have a severe impact on the eye sight. It is a known fact that a significant number of eye related issues are triggered by chronic diabetes. However, the severe infection and genetic factors are also frequently linked with laser probe. The American Academy of Ophthalmology stated that in 2016, more than 4 Mn people with diabetes in the US had visual complications. Demand for laser probe has also increased due to their growing application in dental procedures for periodontal diseases and caries.  The aforementioned factors will continue to support the growth of the market throughout the assessment period.

As per Market Research Future (MRFR)’s analysis with the global laser probe market forecast, industry growth is set to strike a CAGR of 9.11% during the forecast period 2018 to 2023. The valuation of the market is estimated to reach USD 1560.76 Mn by the end of 2023.

Competition Tracking:

Some of the notable players operating in the market include Alcon (Novartis), FCI, Reimers & Janssen GmbH, Transonic Systems Inc., OphthalMed LLC, Iridex Corporation, Bausch & Lomb Incorporated, ADInstruments, Quantel Medical, Omega Laser Systems Limited, Vitreq and Lumenis.

Segmental Analysis:

The report includes a thorough segmental analysis of the market based on probe type, product type, application and end user.

On the basis of product type, the market has been segmented into pulsed laser probes, continuous-wave (CW) laser probes and others. The continuous-wave (CW) laser probes segment currently accounts for the largest  Laser Probe Market share. In addition, the segment will continue to witness a steady growth during the forecast period. CW laser probes find widespread application in dermatological procedures such as wrinkle reduction, and scars or marks removal.

By probe type, the market has been segmented into cluster laser probe, single laser probe and others. The single laser probe segment currently accounts for the largest market share. The segment surpassed a valuation of USD 400 Mn in 2017. The cluster laser probe segment is projected to exhibit the strongest CAGR over 2023. Cluster laser probes are highly advanced and quickly gaining popularity. 

By application, the market has been segmented into dermatology, orthopedics, ophthalmology, dentistry, rheumatology and other. Of these, the ophthalmology segment accounted for the highest market share in 2017 and trends are likely to continue beyond 2018. Whereas, the dermatology segment is set to surge at the highest CAGR during the review period. This is primarily owing to the increased application of laser probes in various types of dermatological procedures.

By end-user, the market has been segmented into clinics, tertiary hospitals and others. Currently, the tertiary hospital segment accounts for the predominant share of the market. The currently market valuation of the segment is more than USD 500 Mn. This is attributed to the rapid proliferation of tertiary hospitals in urban and sub-urban areas.

Regional Outlook:

On the basis of region, the market has been segmented into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa (MEA). North America and Latin America collectively command the most dominant share of the global laser probe market. The increasing prevalence of diseases such as cataract and arthritis and the rising demand for aesthetics is supporting the growth market in these two regions.According to the American Society for Nutrition, in 2016, close to 47% of the adults in the US had periodontal disease. In the same years, 586,662 minimally-invasive cosmetic procedures were performed for laser skin resurfacing. The region will remain a key destination for market players throughout the assessment period.

Worldwide Surgical Sealants and Adhesives Market 2019 Synopsis With Leading Players, Industry Growth Factor Foresight By 2023

Global Surgical Sealants and Adhesives Research Report: by Product (Biological, Synthetic, Fibrin, Collagen, Gelatin), by Indication (Tissue Sealing, Hemostasis), by Application (General Surgeries, Cardiovascular, CNS, Urological) - Forecast Till 2023

Growing prevalence and incidence of various disorders, growth in the number of accidents, and growth in the number of surgeries are expected to drive the growth of market. According to the Centers for Disease Control and Prevention (CDC), each year around 630,000 Americans die from heart disease. On other hand, lack of reimbursements policy; and extensive clinical data requirements for launching products can restrain the market growth over the assessment period.

Global Surgical Sealants and Adhesives Market size is expected to grow significantly over the forecast period. It is anticipated that the market held a market value of USD 2.12 billion in 2017 and is projected to grow at a CAGR of 9.3% over the forecast period.

Regional Analysis

Geographically, the Americas is expected to dominate the global surgical sealants and adhesives market share owing to the presence of well-developed healthcare sector, growing prevalence and incidence of various disorders, growth in the number of accidents, and growth in the number of surgeries. Europe is expected to hold the second largest position in the global surgical sealants and adhesives market owing to the growing prevalence of chronic diseases coupled with increasing adoption of new technologies. Asia-Pacific is expected to be the fastest growing market owing to the large population base of the diabetic patients and increasing developments in healthcare segment. Furthermore, the Middle East and Africa region is expected to account for the least market share in the global surgical sealants and adhesives market.      

Segmentation

The global surgical sealants and adhesives market has been segmented into product, indication, application, and end user.

Based on product, has been segmented into natural/biological sealants and adhesives and synthetic and semisynthetic sealants and adhesives. The natural/biological sealants and adhesives and synthetic segment is accounted for the largest share segment of the market in 2017.

The market, by indication, has been segmented into surgical hemostasis, tissue sealing, and tissue engineering.

The market, by application, has been segmented into general surgeries, cardiovascular surgeries, central nervous system surgeries, orthopedic surgeries, urological surgeries, and others.

Key players

Bard, Inc. (US), Johnson & Johnson (UK), Baxter International, Inc. (US), Medtronic plc (US), B. Braun Melsungen AG (Germany), Cohera Medical, Inc. (US), Sanofi Group (France), Sealantis, Ltd (Israel), Vivostat A/S (Denmark), and Ocular Therapuetix, Inc. (US) are some of the key players in the global surgical sealants and adhesives market.

Animal Genetics Industry Overview By Growth Factors, Product Chain Value, Competitors Analysis And Forecast 2023

Market Scenario:

Animal genetics is a branch of genetics that pacts with the study of genetic variation and inheritance, primarily for domestic and wild animals. The Animal Genetics Market is expected to witness tremendous growth owing to as increased adoption of genetic services to prevent genetic diseases and business loss, and rising acceptance of advanced genetic technologies. Other key factors such significant investments in R&D and expansions undertaken by key players are contributing towards the growth of the market. However, challenges such as need for specific breeding programs for breeds with inferior economic performance, and economic sustainability in local breeds is likely to curb the market growth during the forecast period.

For the commercial level, animal genetics is used for services such as DNA typing, genetic disease testing, and genetic trait testing. This methodology uses hybrid population, ontogenetic, and cytological studies for determining the genetic hybridizations. For instance, a genetically modified cow might be able to produce more milk and can be less prone to common cattle diseases, such as clostridial disease, bovine respiratory disease complex, etc., thus, effectively increasing overall profit of the cattle farmers 

The Global Animal Genetics Market size is projected to register a CAGR of 8.4% over the forecast period.

The key factor responsible for influencing this market is increasing consumption of animal-derived protein, growing global population and rapid urbanization, and growing focus on identifying superior breeds have aided the growth of the toxicology testing market. However, factors such as, the high cost of animal testing, stringent regulatory framework for genetic engineering, and lack of skilled professionals and are expected to restrict the market growth during the forecast period.

Key players:

• Neogen Corporation (US),
• Genus (UK),
• URUS (US),
• EW Group (Germany),
• Groupe Grimaud (France),
• CRV Holding B.V. (The Netherland),
• Topigs Norsvin (Netherlands),
• Zoetis (US),
• Envigo (US)
• Hendrix Genetics BV (The Netherland),
• Animal Genetics (US),
• Alta Genetics (US),
• vetGen (US)

Segmentation:The Animal Genetics Market Global is segmented into animal genetic products, services, and end-user. The Animal Genetics Market, by animal genetic products, the market is segmented into genetic materials and live animals. The live animals are further bifurcated into poultry, bovine, porcine, canine and others. The genetic materials are sub-segmented into semen and embryo. On the basis of services, the animal genetics market is bifurcated into genetic disease tests, DNA typing, gene trait tests, and others. On the basis of end-user, the market is segmented into veterinary hospitals & clinics, diagnostic centers, research centers and institutes, and others

Regional Market Summary 

The Americas is the largest in the market owing to the high acceptance of animal genetics in research, the development in research expenditure along with the increasing acquisition by the market players are also accountable for the growth of the animal genetics market. For instance, in 2018, Neogen completed the acquisition of Livestock Genetic Services, a firm that specializes in genetic evaluations and data management for cattle-breeding organizations. This strategy enhances the company’s in-house genetic evaluation capabilities and further expands the company’s global network of animal genomics laboratories.

The European region is the second largest animal genetics market over the forecast period due to high consciousness about animal wellbeing coupled with increased expenditure on veterinary services in the region. As per a report by the European Pet Food Industry Federation, more than 75 million households in Europe own a pet.

The Asia Pacific region is likely to develop at the uppermost CAGR for the animal genetics market in the years to come. Moreover, the rising veterinary care services both at the veterinary hospital and at community level are expected to influence the market in a positive way.

The Middle East and Africa accounts for the least share due to low per capita income and lack of availability of well-trained healthcare professionals. However, there has been an increasing demand for test accuracy and consistency among end-users and the government in this region that is enhancing the adoption of animal genetic technology in this region.

Epilepsy Diagnosis & Treatment Market Opportunities, Drivers, Manufacturers, Analysis And Forecasts Till 2023

Synopsis of the Global Epilepsy Diagnosis & Treatment Market
Increasing prevalence of epilepsy, rising number of traumatic brain injury cases, growing geriatric population, and rising healthcare expenditures are the major drivers for the global epilepsy diagnosis and treatment market trends. However, high cost of therapeutic surgeries, low per capita healthcare expenditure, and lack of awareness for the disease in emerging economies are estimated to restrain the market growth during the projected period. The global epilepsy diagnosis and treatment market is estimated to grow at an approximate CAGR of 6.3% during the forecast period.
Segmentation
The global epilepsy diagnosis and treatment market is segmented on the basis of type, diagnosis, treatment, and end-user. On the basis of type, the market is segmented into idiopathic, cryptogenic, symptomatic, and others. On the basis of diagnosis, the market is segmented into neurological exam, blood test, imaging, and others. The imaging segment is sub-segmented into electroencephalogram, computerized tomography, magnetic resonance imaging, positron emission tomography, and others. On the basis of treatment, the market is segmented into medication, surgery, brain stimulation, and others. The medication segment is sub-segmented into acetazolamide, carbamazepine, clobazam, and others. The surgery segment is sub-segmented into hemispherectomy, corpus callosotomy, resection surgery, and others. The brain stimulation segment is sub-segmented into deep brain stimulation, responsive neurostimulation, and others. On the basis of end user, the market is segmented into hospitals & clinics, diagnostic centers, and others.
Regional Analysis
The Americas dominate the global epilepsy diagnosis and treatment market, which can be attributed to the presence of a well-developed healthcare sector and huge patient population within the region. Moreover, increasing number of head trauma cases boosts the American market. Europe holds the second largest market share owing to the availability of funds for research, presence of a well-developed healthcare sector, and government support. Followed by Europe, the Asia Pacific region is projected to be the fastest growing region for the global epilepsy diagnosis and treatment market. Presence of developing healthcare sector, along with emerging economies of the Asia Pacific region boosts the market growth. The Middle East & Africa has the least share in the global epilepsy diagnosis and treatment market, owing to the low per capita healthcare expenditures, lack of awareness for the disease, and stringent government policies, especially in the African region. On the other hand, the Middle East region within the Middle East & Africa is estimated to be fastest growing region due to growing healthcare expenditures and presence of the developed economies, such as Kuwait, Qatar, Dubai, and others.
Key Players
The key players for the global epilepsy diagnosis and treatment market are Pfizer, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), UCB Pharma Ltd. (U.K), Abbott (U.S.), GlaxoSmithKline plc (U.K), Novartis International AG (Switzerland), Sanofi S.A. (France), Shire (Republic of Ireland), Medtronic (U.S.), NeuroWave Systems Inc. (U.S.), Natus Medical Incorporated. (U.S.), Siemens Ltd. (Germany), and others.

Global Ebstein’s Anomaly Market Solid Segment Analyzed By Latest Trends, Growth Rate And 2023 Insight

Market Scenario:

Ebstein's anomaly is a rare congenital disease that occurs due to improper development of the tricuspid valve in the first eight weeks of fetal growth. This disorder occurs when the tricuspid valve that divides the two chambers of the right side of the heart does not form correctly.

The global Ebstein’s Anomaly market is driven by the increasing number of congenital heart diseases and growing population; growing market players has increased the scope of Ebstein’s Anomaly market. Technological advancements, owing to which new and advanced products are being launched in the market, is another factor propelling the growth of this market.

Ebstein's anomaly may be due to many factors, including genetics and the environment. Children born in a family with a history of heart defects may be more likely to have Ebstein's anomaly. The mother's exposure to certain medications, such as lithium, can lead to Ebstein's anomaly in the child.

However, varied stringency of regulatory procedures across the globe and the presence of complex regulatory procedures may hinder the growth of this market.

The global Ebstein’s Anomaly market share is expected to grow at a CAGR of 9.0% during the forecast period.

Key Players                                                                                                         

Some of the key players in fungal eye infection market are Ebstein’s Anomaly market are Abbott Vascular, Boston Scientific Corporation, Cordis Corporation, Edwards Lifesciences, Ge Healthcare, Gore Medical, Medtronic, Inc., Numed, Inc., Siemens Healthcare, St. Jude Medical, and Toshiba Corporation among others.

Segmentation                                                                                                                                            

The global Ebstein’s Anomaly market is segmented on the basis of treatment, diagnosis and end users.

On the basis of diagnosis Ebstein’s Anomaly market is segmented into echocardiogram, electrocardiogram (ECG) chest x-ray, cardiac MRI, Holter monitor, pulse oximetry, exercise stress test, electrophysiology study, and cardiac catheterization.

On the basis of the treatment, the market is segmented medications and surgical treatment. Surgical Treatment is further segmented into tricuspid valve repair, tricuspid valve replacement, closure of the atrial septal defect, and maze procedure.

On the basis of end users, the market is segmented into hospitals & surgical centers, and specialty clinics.

Regional Analysis

North America Ebstein’s Anomaly market is rapidly growing in the American region. On a regional basis, the Americas is segmented into North America and South America. North America is segmented into the U.S. and Canada. Increasing number of congenital disorders and growing  population has increased the scope for the Ebstein’s Anomaly market in North America. According to CDC (Centre for Disease Control), it was estimated that about 1 million U.S. children and about 1.4 million U.S. adults were living with CHDs.  Additionally, CHDs affect nearly 1% of―or about 40,000―births per year in the United States.

Europe is the second largest market and holds a healthy share in the global Ebstein’s Anomaly market. The European market is expected to grow steadily during the forecast period owing to the skilled professionals and availability of advanced and accessible treatment facilities. Additionally, wide research and development activities for the treatment of rare disease and increasing government funding boost the market growth.  

Asia Pacific is expected to be the fastest growing market. Increasing prevalence of chronic diseases such as diabetes is the major driver for the market growth. India is the fastest growing region owing to the increasing population. Rising awareness about the health and availability of new treatment methods drive the market in this region. Rising healthcare expenditure and overall growth of healthcare diagnostic and treatment industry also drives the market.

The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access and availability of treatment facilities. In the Middle East, United Arab Emirates is the largest market share owing to the development of healthcare industry and rising availability of specialty care centers.

Worldwide Dry Eye Syndrome Market Ready To Set Outstanding Growth From 2019 To 2023

Global Dry Eye Syndrome research report, by type (evaporative, aqueous), by diagnosis (schirmer test, eye exam), treatment (nutritional supplements, surgery), distribution channel (hospital pharmacies) end user (hospitals) - global forecast till 2023

Increasing geriatric population, rising prevalence of the diseases like diabetes, rheumatoid arthritis, growing per capita healthcare expenditure, and changing lifestyle are the major drivers for the market growth. However, factors like stringent FDA drug approvals, lack of skilled ophthalmologists, and low per capita healthcare expenditure in the middle and low income countries are estimated to restrain the market growth during the forecast period. 

The global dry eye syndrome market growth is expected to advance with an approximate CAGR of 6.6% during the forecast period.

According to the World Health Organization in 2016, approximately 422 million adults were globally affected by diabetes in 2014, as compared to 108 million in the 1980’s. Moreover, in 2014, it was estimated that the global prevalence of diabetes was estimated to be around 8.5%. Additionally, rising per capita healthcare expenditure, and changing lifestyle boosts the market. However, factors like stringent FDA drug approvals, lack of skilled ophthalmologists, and low per capita healthcare expenditure in the middle-and low-income countries are restraining the market. 

Tears provide lubrication, limits the risks of eye infections, washes away the foreign matter, thus, are helpful in keeping the surface of the eyes smooth and clear. Dry eye syndrome is a medical condition in which eyes’ lubrication is hindered by the unavailability of tears. Under normal condition, during excessive production, tears flow into the small drainage ducts of the inner corners of the eyes, followed by draining back into the nose. Sometimes when the production of tears and drainage is not balanced, it can result into dry eye syndrome. Eye redness, sensitivity to light, watery eyes, eye fatigue are some of the common symptoms of the disease. Increasing geriatric population, rising prevalence of diseases like diabetes, rheumatoid arthritis, and others are estimated to be the major drivers for the market growth.

Key Players

The key players for the global dry eye syndrome are Allergan (Republic of Ireland), Novartis AG (Switzerland), Otsuka Pharmaceutical Co. Ltd. (Japan), Valent Pharmaceuticals (Canada), Johnson & Johnson Vision (U.S.), Acadia Pharmaceutical (U.S.), Allostera Pharma (Canada), I-Med Pharma Inc. (Canada), Santen Pharmaceuticals Co. Ltd., (Japan), AFT pharmaceuticals (New Zealand), Novaliq GmBh (Germany), Auven therapeutics (U.S.), and others.

Segmentation

The global dry eye disease market is segmented on the basis of the type, diagnosis, treatment, distribution channel and end user.

On the basis of the type, the market is segmented into evaporative dry eye syndrome aqueous dry eye syndrome, and others. On the basis of the diagnosis, the market is categorized into Schirmer test, eye exam, and others.  On the basis of the treatment, the market is segmented into nutritional supplements, serum eye drops, lubricant eye drops, anti-inflammatory drugs segments, surgery, and others. The lubricant eye drops segment is sub-segmented into oily tear eye drops, ointments, preservative-free drops, and others. The anti-inflammatory drugs segments segement is sub-segmented into tetracyclines, corticosteroids, and others. The surgery segment is sub-segmented into punctal occlusion, intense pulsed light therapy, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others.  On the basis of the end users, the market is segmented into hospitals, clinics, home care, and others.

Regional Analysis

The Americas dominates the global dry eye syndrome market owing to the presence of a well-developed healthcare sector, huge patient population, and increasing healthcare expenditure. Moreover, the presence of the major market players like Johnson & Johnson Vision, Auven therapeutics, Acadia Pharmaceutical, and others within the region boosts the market growth. Europe stands second in the dry eye syndrome market. This is attributed to the increasing availability of funds for research, a well-developed healthcare sector, huge patient and growing geriatric population. The Asia Pacific region is estimated to be the fastest growing region for the market. Economies like India, China, Australia and others within the region have huge patient population, rising healthcare expenditure facilitating the market growth. On the other hand, the Middle East & Africa has the least share in the global dry eye syndrome. Low per capita healthcare expenditure, stringent government policies, especially within the African region restrains the market growth within the region. The Middle East holds a majority of the market due to a well-developed healthcare sector and huge healthcare expenditure.

World Diastematomyelia Market Estimation Of Top Key Players Shares, Revenue, Analysis And Forecasts Till 2023

Market Scenario

Diastematomyelia is a rare anomaly resulting in the vertical splitting of the spinal cord. Females are more susceptible to this disease than males. According to the World Health Organization (2015), 1 in 2000 people suffers from this disease. However, during the last few years, the prevalence rate is increasing continuously. Increasing number of patients suffering from the disease, rising geriatric population and rising government support for research & development have driven the growth of the market. Moreover, rising demand for the better treatment, and changing lifestyle habits have fuelled the growth of the market. However, the cost of the surgery is too high and is not affordable to the people in developing region. Thus, the high cost of treatment may restrain the market.

A number of diagnostic procedures are available in the market for the diagnosis of the diastematomyelia. Increasing healthcare expenditure and rising government support have supported the growth of the market. According to the Boston Children's Hospital, in 2015, 5% of children across the globe were suffering from sustain spinal cord injuries. Furthermore, rapid development in the imaging technology and continuous improvement in the medical services have fuelled the market growth. The cost associated with the surgeries is very high which is not affordable for the people in developing region. Thus, high cost of surgeries, and lack of the precise treatment may restrain the growth of the diastematomyelia market trends.

The Global Diastematomyelia Market is expected to grow at a CAGR of 8.3% during forecast period 2017-2023.

Key players

The major key players in the global diastematomyelia market: 3M (US), GlaxoSmithKline PLC (U.K), Pfizer Inc. (U.S.), Lineage Medical, Inc. (U.S.), Johnson & Johnson Services Inc. (U.S.), Bristol-Myers Squibb and Company (U.S.), B. Braun (Germany), Stryker Corporation (U.S.), Argon Medical Devices, Inc (the Netherlands), Cook Medical (U.S.)

SegmentationThe global diastematomyelia market is segmented on the basis of types, host, therapy, and end users.

On the basis of type, the market is segmented into dual dural sac (type 1), and single sac (type 2).

On the basis of host, the market is segmented into children and adults.

On the basis of therapy, the market is segmented into diagnosis & therapy. The diagnosis is further segmented into imaging techniques, and prenatal ultrasound. Imaging techniques are further categorised into Plain X-ray, CT, MRI and others. The therapy is further segmented into surgical intervention, scoliosis surgery, decompression (surgery), and others.

On the basis of end users, the market is segmented into hospital, clinics, ambulatory centers, and others.

Regional Analysis

Asia Pacific is the fastest growing region in the global diastematomyelia market owing to the presence of huge patient pool, rapidly developing economies, and increasing demand for the better treatment options. Majority of the market is driven by India and China owing to huge patient population.

The Americas dominates the global diastematomyelia market owing to large patient population. According to the Brain and Spinal Cord Injury Rehabilitation, in 2015, over 259,000 people in the U.S. were suffering from spinal cord injury. Increasing number of patients suffering from diastematomyelia and other spinal disease have driven the growth of the Americas diastematomyelia market. Additionally, high per capita income and increasing government support for research & development will fuelled the growth of the market. Diastematomyelia is considered as a rare diseases thus, government and other private companies are trying to create awareness among the people by conducting different seminars. Increasing awareness among people regarding the disease and well-developed technology will create opportunities for the development of the market.

Europe accounts for the second largest diastematomyelia market, which is followed by Asia Pacific. Availability of funds for research, huge geriatric population, and government support for research & development projected to drive the market in Europe. The U.K and Germany are the major contributors for the market.

Whereas, the Middle East & Africa owns the least share of the global diastematomyelia market due to the presence of poor economy, especially, in the Africa region. The market of this region is dominated by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure. However, Africa region shows the fastest growth for the market.